Initial results of a phase III study show safety of HRT and low dose tamoxifen.

Abstract

1009 Background: HRT is beneficial on menopausal disturbancies and decreased bone fracture risk and colorectal cancer (CRC), but increased VTE, cardiovascular events and breast cancer in the WHI trial. However, the WHI characteristics (median age 63.3 yrs, median BMI 28.5, use of oral HRT) diminish generalization of results. The WHI trial shows an increased… (More)

Topics

Cite this paper

@article{Bonanni2006InitialRO, title={Initial results of a phase III study show safety of HRT and low dose tamoxifen.}, author={Beatrice Bonanni and Barbara Santillo and D. Correas Serrano and Umberto Veronesi and Marco Rosselli del Turco and P. G. Masullo and N. Ceppi Monti and Chiara Andreoli and Andrea U. Decensi}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={1009} }